Reuters logo
BRIEF-Spark Therapeutics says 3-year follow-up phase 3 data provide additional information on Luxturna
November 10, 2017 / 10:28 PM / 7 days ago

BRIEF-Spark Therapeutics says 3-year follow-up phase 3 data provide additional information on Luxturna

Nov 10 (Reuters) - Spark Therapeutics Inc:

* Three-Year follow-up phase 3 data provide additional information on efficacy, durability and safety of investigational Luxturna(voretigene neparvovec) in patients with biallelic RPE65-mediated inherited retinal disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below